EAIR. Atrial fibrillation, including atrial fibrillation and flutter (A), symptomatic ventricular arrhythmia (B), and hypertension in patients treated with zanubrutinib or ibrutinib (C) in ASPEN cohort 1, ALPINE, pooled analysis of the 2 studies (ASPEN/ALPINE), and pooled analysis of 1550 patients with B-cell malignancies. Hypertension in patients treated with zanubrutinib in 9 clinical studies (D). Studies BGB-3111-210 and BGB-3111-1002 were pooled for this analysis to increase the number of patients, and BGB-3111-LTE studies were pooled into the corresponding parental studies. The dashed line indicates the EAIR of hypertension in the pooled analysis of 1550 patients with B-cell malignancies (0.57 persons per 100 person-months). LTE, long-term extension; NA, not applicable; NC, not calculated.